Table 1.
Phenotypical characterization of RMS cell lines
| A204 (ERMS) | RD (ERMS) | RH30 (ARMS) | RH41 (ARMS) | TE671 (ERMS) | |
|---|---|---|---|---|---|
| KIR ligand | |||||
| HLA-I | ++ | + | ++ | − | + |
| NKG2D ligands | |||||
| MICA/B | ± | ++ | − | − | − |
| MICA | − | + | − | − | − |
| ULBP1 | − | ± | − | ± | ± |
| ULBP2 | − | ± | − | ± | + |
| ULBP3 | ± | + | ± | + | + |
| DNAM-1 ligands | |||||
| CD112 | + | ++ | ± | ++ | ++ |
| CD155 | + | + | + | ++ | ++ |
| NCR ligands | |||||
| NKp30L | − | − | − | − | − |
| NKp44L | − | − | − | − | − |
| NKp46L | − | − | − | − | − |
Expression of ligands for the inhibitory/activating NK cell receptors KIRs and the inhibitory receptor NKG2A/CD94 (HLA class I) and for the activating NK cell receptors (NKG2D, DNAM-1 and NCRs) was determined on RMS cell lines by flow cytometry. Mean fluorescence intensity (MFI) ratio of specific staining versus isotype control is depicted as:− = <2; ± = 2–5; + = 5–10; ++ = >10. ERMS embryonal rhabdomyosarcoma, ARMS alveolar rhabdomyosarcoma